国际妇产科学杂志 ›› 2017, Vol. 44 ›› Issue (1): 64-66.

• 综述 • 上一篇    下一篇

妊娠期应用生长抑素类似物对母胎安全性的研究进展

黄亚绢,宋健   

  1. 上海交通大学附属第六人民医院
  • 收稿日期:2016-06-15 修回日期:2016-09-07 出版日期:2017-02-15 发布日期:2017-03-28
  • 通讯作者: 黄亚绢 E-mail:mozhi@sjtu.edu.cn

The Progress for the application security of somatostatin analogues on mother and fetus in pregnancy.

  • Received:2016-06-15 Revised:2016-09-07 Published:2017-02-15 Online:2017-03-28

摘要: 生长抑素(Somatostatin,SST)是一种抑制多种激素释放的调节肽,具有广泛的内分泌抑制作用,其类似物在上消化道出血、急性胰腺炎、肢端肥大症等疾病中被广泛使用。虽然美国FDA将其评为B级药物,并且国内外临床医师对于妊娠合并上述疾病患者时常使用该类药物治疗,但它在人类妊娠期使用的安全性及对母胎的近远期影响目前尚存无定论,有待进一步研究。综述妊娠期使用生长抑素类似物安全性的研究进展。

关键词: 生长抑素类似物, 妊娠期, 母胎, 安全性

Abstract: Somatostatin(SST)is a regulatory peptide, inhibiting the release of many hormones , with a wide range of endocrine inhibitory effect on diseases such as upper gastrointestinal bleeding, acute pancreatitis and acromegaly. The FDA has recognized somatostatin analogues as Class B drugs,and the domestic and foreign clinicians often use them to treat the pregnancy-complicated diseases,but the application security of them in human pregnancy is still inconclusive and worth further studying. Progress for the application security of somatostatin analogues on mother and fetus in pregnancy.

Key words: Somatostatin analogue, Pregnancy, Mother and Fetus, Security

中图分类号: